TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: Possible effect in melancholic and psychotic depression

Neuropsychobiology

Volumn 67, Issue 1, 2013, Pages 41-47

  Arias, Bárbara ^a,c   Fabbri, Chiara ^d   Gressier, Florence ^e   Serretti, Alessandro ^d,f   Mitjans, Marina ^a   Gastó, Cristóbal ^b,c   Catalán, Rosa ^b,c   De Ronchi, Diana ^d   Fañanás, Lourdes ^a,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e BICÊTRE HOSPITAL   (France)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antidepressants; Citalopram; Genes; Genetic polymorphism; Major depression; Psychosis; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; NORCITALOPRAM; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; DEPRESSIVE PSYCHOSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MELANCHOLIA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ALLELES; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MALE; MONOAMINE OXIDASE; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE;

EID: 84870380950     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000343388     Document Type: Article

References (36)

1. Franchini L, Serretti A, Gasperini M, Sme-raldi E: Familial concordance of fluvox-amine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255-259.
2. Nielsen DA, Jenkins GL, Stefanisko KM, Jefferson KK, Goldman D: Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7. Brain Res Mol Brain Res 1997; 45: 145-148.
3. Jonsson EG, Goldman D, Spurlock G, Gus-tavsson JP, Nielsen DA, Linnoila M, Owen MJ, Sedvall GC: Tryptophan hydroxylase and catechol-o-methyltransferase gene polymorphisms: relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Eur Arch Psychiatry Clin Neuro-sci 1997; 247: 297-302.
4. Serretti A, Zanardi R, Cusin C, Rossini D, Lorenzi C, Smeraldi E: Tr y ptopha n hydrox y-lase gene associated with paroxetine antide-pressant activity. Eur Neuropsychopharma-col 2001; 11: 375-380.
5. Serretti A, Zanardi R, Rossini D, Cusin C, Lilli R, Smeraldi E: Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol Psychiatry 2001; 6: 586-592.
6. Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Su-gawara K, Otani K: Monoamine oxidase: a gene polymorphism, tryptophan hydroxy-lase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder. Prog Neuro-psychopharmacol Biol Psychiatry 2002; 26: 1279-1283.
7. Ham BJ, Lee MS, Lee HJ, Kang RH, Han CS, Choi MJ, Lee SH, Ryu SH: No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population. Psychiatr Genet 2005; 15: 299-301.
8. Hong CJ, Chen TJ, Yu YW, Tsai SJ: Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacoge-nomics J 2006; 6: 27-33.
9. Kato M, Wakeno M, Okugawa G, Fukuda T, Azuma J, Kinoshita T, Serretti A: No association of TPH1218A/C poly morphism with treatment response and intolerance to SSRIs in Japanese patients with major depression. Neuropsychobiology 2007; 56: 167-171.
10. Ili A, Setala-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimaki T, Leinonen E, Kampman O: 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 AND TPH2 polymorphisms and major depression. Neuroreport 2009; 20: 1125-1128.
11. Wang HC, Yeh TL, Chang HH, Gean PW, Chi MH, Yang YK, Lu RB, Chen PS: TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients. Psychopharmacology (Berl) 2011; 213: 773-779.
12. Viikki M, Kampman O, Illi A, Setala-Soik-keli E, Anttila S, Huuhka M, Nuolivirta T, Poutanen O, Mononen N, Lehtimaki T, Leinonen E: TPH1218A/C polymorphism is associated with major depressive disorder and its treatment response. Neurosci Lett 2010; 468: 80-84.
13. Porcelli S, Drago A, Fabbri C, Gibiino S, Ca-lati R, Serretti A: Pharmacogenetics of anti-depressant response. J Psychiatry Neurosci 2011; 36: 87-113.
14. Sabol SZ, Hu S, Hamer D: A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 1998; 103: 273-279.
15. Mongeau R, Martin CB, Chevarin C, Maldo-nado R, Hamon M, Robledo P, Lanfumey L: 5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment. J Neurochem 2010; 115: 438-449.
16. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldman D: Modification of human 5-HT(2C) receptor function by Cys-23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry 2004; 9: 55-64.
17. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S, Del Favero J, Di-keos DG, Kaneva R, Lilli R, Massat I, Mila-nova V, Muir W, Noethen M, Oruc L, Petro-va T, Papadimitriou GN, Rietschel M, Serretti A, Souery D, Van Gestel S, Van Broeckhoven C, Mendlewicz J: Variability of 5-HT2C receptor Cys23Ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001; 6: 579-585.
18. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP: Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879-889.
19. Arias B, Serretti A, Mandelli L, Gasto C, Catalan R, Ronchi DD, Fananas L: Dysbindin gene (DTNBP1) in major depression: association with clinical response to selective serotonin reuptake inhibitors. Pharmacogenet Genomics 2009; 19: 121-128.
20. Baffa A, Hohoff C, Baune BT, Muller-Tidow C, Tidow N, Freitag C, Zwanzger P, Deckert J, Arolt V, Domschke K: Norepine phrine and serotonin transporter genes: impact on treatment response in depression. Neuro-psychobiology 2010; 62: 121-131.
21. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K: Serotonin receptor 1A-1019C/G variant: impact on antidepres-sant pharmacoresponse in melancholic depression? Neurosci Lett 2008; 436: 111-115.
22. Dannon PN, Lowengrub K, Gonopolski Y, Kotler M: Current and emerging somatic treatment strategies in psychotic major depression. Expert Rev Neurother 2006; 6: 73-80.
23. Peselow ED, Sanfilipo MP, Difiglia C, Fieve RR: Melancholic/endogenous depression and response to somatic treatment and placebo. Am J Psychiatry 1992; 149: 1324-1334.
24. Amsterdam JD: Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 1998; 12: S99-S111.
25. Clerc GE, Ruimy P, Verdeau-Palles J: A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafax-ine French Inpatient Study Group. Int Clin Psychopharmacol 1994; 9: 139-143.
26. DeBattista C, Hawkins J: Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 2009; 23: 369-377.
27. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L: 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23: 563-567.
28. Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW: Association study of a mono-amine oxidase A gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychophar-macology 2005; 30: 1719-1723.
29. Lappalainen J, Long JC, Virkkunen M, Oza-ki N, Goldman D, Linnoila M: HTR2C Cys-23Ser polymorphism in relation to CSF monoamine metabolite concentrations and DSM-III-R psychiatric diagnoses. Biol Psychiatry 1999; 46: 821-826.
30. Schatzberg AF, Rothschild AJ: Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV? Am J Psychiatry 1992; 149: 733-745.
31. Tzeng DS, Chien CC, Lung FW, Yang CY: MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol 2009; 24: 293-300.
32. Cusin C, Serretti A, Zanardi R, Lattuada E, Rossini D, Lilli R, Lorenzi C, Smeraldi E: Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. Int J Neuropsycho-pharmacol 2002; 5: 27-35.
33. Kato M, Serretti A: Review and meta-analy-sis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500.
34. Schatzberg AF, Rothschild AJ: Serotonin activity in psychotic (delusional) major depression. J Clin Psychiatry 1992; 53(suppl):52-55.
35. Serretti A, Kato M, Kennedy JL: Pharmaco-genetic studies in depression: a proposal for methodologic guidelines. Pharmacogenom-ics J 2008; 8: 90-100.
36. Cavalli-Sforza LL, Piazza A: Human genom-ic diversity in Europe: a summary of recent research and prospects for the future. Eur J Hum Genet 1993; 1: 3-18.